NB4168 / Niagen Bioscience - LARVOL DELTA

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 (Businesswire) - "Under the collaboration, Evotec will conduct pharmacokinetic and pharmacodynamic studies and validate bioanalytical methods to further characterize NB4168 and support Niagen Bioscience’s preclinical and Investigational New Drug (IND)-enabling development activities. NB4168 is Niagen Bioscience’s proprietary oral small-molecule candidate initially developed for Ataxia Telangiectasia (A-T), a rare pediatric genetic disease with no approved treatments."

Licensing / partnership • Preclinical • Genetic Disorders • Rare Diseases

Niagen Bioscience, Inc…announced…that the U.S. Food and Drug Administration granted Rare Pediatric Disease Designation for its drug candidate NB4168 for the treatment of Ataxia Telangiectasia. (Investing.com) - "The European Medicines Agency also granted Orphan Medicinal Product Designation to NB4168 for the same condition"

Orphan drug • CNS Disorders • Genetic Disorders • Rare Diseases